Lupin shares drop as Citi downgrades to Sell, slashes target price
Citi cuts Lupin's rating to Sell with a reduced target of Rs 2,050, citing US business slowdown.
1Citi's stark downgrade
Citi downgraded Indian pharma major Lupin to Sell and reduced its target price to Rs 2,050. This decision reflects anticipated slowdown in Lupin's core US business. Analysts cut FY27 EPS estimates by 14%. Following the announcement, Lupin shares fell 2% in Mumbai trading.
2US market contraction
The report projects Lupin's US base business to decline to $975 million by FY29. This downturn stems from intensifying generic drug competition and pricing pressures. Citi expects new product launches to provide insufficient offset to this decline.
3Margin pressures mount
The investment bank foresees significant margin compression for Lupin. Rising input costs and US regulatory challenges are negatively impacting profitability. Citi estimates FY27 EBITDA margins could fall below 15%, down from current levels.
4Technical indicators weaken
Lupin's stock shows technically bearish signals. While RSI indicates oversold conditions, other oscillators support the downtrend. Trading below its 200-day moving average, the stock may test support at Rs 1,900 in the near term.
5Sector-wide headwinds
India's pharmaceutical sector faces pressure from global economic uncertainties. Peers like Zydus Lifesciences and Cipla confront similar challenges. The pharma index has underperformed the Nifty by 8% over the past three months.
6Analyst reactions
Citi's revision may prompt other analysts to revisit their estimates. Currently, 18 of 32 analysts rate Lupin as Hold or Sell. The average target price stands at Rs 2,450, but downward revisions are expected following this report.
7Investor risk factors
Lupin's US market weakness affects 45% of total revenues. FDA approval delays and generic drug pricing declines could create additional pressure. Investors are closely monitoring the company's performance in Europe and emerging markets.
8Long-term outlook
Citi's report emphasizes Lupin's need for strategic restructuring. Focusing on high-margin products like biosimilars and complex generics appears critical for long-term growth. However, this transition is expected to take at least 2-3 years to materialize.